Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study

Authors: Brown, Jennifer R. ^{1, ∗}, Li, Jessica ², Eichhorst, Barbara F. ³, Lamanna, Nicole ⁴, O’Brien, Susan M. ⁵, Tam, Constantine S. ⁶, Qiu, Lugui ^{7, 8}, Huang, Ruiqi ⁹, Shi, Yang ¹⁰, Idoine, Adam ², Salmi, Tommi ¹¹, Cohen, Aileen Cleary ², Shadman, Mazyar ¹²

Source: In Blood Advances 22 April 2025 9(8):1918-1926

Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL

Authors: Gauthier, Jordan ^{1, 2, ∗}, Liang, Emily C. ^{1, 2}, Huang, Jennifer J. ^{1, 2}, Kimble, Erik L. ^{1, 2}, Hirayama, Alexandre V. ^{1, 2}, Fiorenza, Salvatore ³, Voutsinas, Jenna M. ¹, Wu, Qian (Vicky) ¹, Jaeger-Ruckstuhl, Carla A. ¹, Pender, Barbara S. ¹, Kirchmeier, Delaney R. ¹, Torkelson, Aiko ¹, Braathen, Kristina ¹, Basom, Ryan ¹, Shadman, Mazyar ^{1, 2}, Kopmar, Noam E. ^{1, 2}, Cassaday, Ryan D. ^{1, 2}, Riddell, Stanley R. ^{1, 2}, Maloney, David G. ^{1, 2}, Turtle, Cameron J. ^{1, 3}

Source: In Blood Advances 22 April 2025 9(8):1861-1872

Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas

Authors: Chong, Elise A. ¹, Penuel, Elicia ², Napier, Ellen B. ¹, Lundberg, Rachel K. ¹, Budde, Lihua E. ³, Shadman, Mazyar ⁴, Matasar, Matthew J. ⁵, Bartlett, Nancy L. ⁶, Flinn, Ian W. ⁷, Bosch, Francesc ⁸, Fay, Keith ⁹, Goy, Andre ¹⁰, Kumar, Anita ¹¹, Nastoupil, Loretta J. ¹², Wei, Michael C. ², Wu, Mei ², Yin, Shen ², Fraietta, Joseph A. ^{13, 14}, Chong, Emeline R. ¹, Schuster, Stephen J. ^{1, ∗}

Source: In Blood Advances 25 February 2025 9(4):696-703

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Authors: Sehn, Laurie H. ¹, Bartlett, Nancy L. ², Matasar, Matthew J. ³, Schuster, Stephen J. ⁴, Assouline, Sarit E. ⁵, Giri, Pratyush ⁶, Kuruvilla, John ⁷, Shadman, Mazyar ⁸, Cheah, Chan Yoon ⁹, Dietrich, Sascha ¹⁰, Fay, Keith ¹¹, Ku, Matthew ¹², Nastoupil, Loretta J. ¹³, Wei, Michael C. ¹⁴, Yin, Shen ¹⁴, To, Iris ¹⁴, Kaufman, Derrick ¹⁴, Kwan, Antonia ¹⁴, Penuel, Elicia ¹⁴, Bolen, Christopher R. ¹⁴, Budde, Lihua E. ^{15, ∗}

Source: In Blood 13 February 2025 145(7):708-719

Development and validation of predictive models of early immune effector cell–associated hematotoxicity

Authors: Liang, Emily C. ^{1, 2}, Huang, Jennifer J. ^{1, 2}, Portuguese, Andrew J. ^{1, 2}, Ortiz-Maldonado, Valentín ^{1, 3}, Albittar, Aya ¹, Wuliji, Natalie ^{1, 2}, Basom, Ryan ¹, Jeon, Yein ², Wu, Qian ¹, Torkelson, Aiko ¹, Kirchmeier, Delaney ¹, Chutnik, Abigail ¹, Pender, Barbara ¹, Sorror, Mohamed ^{1, 2}, Hill, Joshua A. ^{1, 2}, Kopmar, Noam E. ^{1, 2}, Banerjee, Rahul ^{1, 2}, Cowan, Andrew J. ^{1, 2}, Green, Damian ⁴, Gopal, Ajay K. ^{1, 2}, Poh, Christina ^{1, 2}, Shadman, Mazyar ^{1, 2}, Hirayama, Alexandre V. ^{1, 2}, Till, Brian G. ^{1, 2}, Kimble, Erik L. ^{1, 2}, Iovino, Lorenzo ^{1, 2}, Chapuis, Aude G. ^{1, 2}, Otegbeye, Folashade ^{1, 2}, Cassaday, Ryan D. ^{1, 2}, Milano, Filippo ^{1, 2}, Turtle, Cameron J. ⁵, Maloney, David G. ^{1, 2}, Gauthier, Jordan ^{1, 2, ∗}

Source: In Blood Advances 11 February 2025 9(3):606-616

Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States

Authors: Davids, Matthew S. ^{1, ∗}, Ambrose, Jacob ², de Nigris, Enrico ³, Prescott, Jennifer ⁵, Leng, Siyang ⁴, Farooqui, Mohammed Z. H. ⁴, Gandra, Shravanthi R. ⁶, Zettler, Christina M. ², Fernandes, Laura L. ², Wang, Ching Kun ², Shadman, Mazyar ⁷

Source: In Blood Neoplasia February 2025 2(1)

A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up

Authors: Tuazon, Sherilyn A. ^{1, 2, 3, 4}, Portuguese, Andrew J. ^{1, 2}, Pont, Margot J. ¹, Cowan, Andrew J. ^{1, 2}, Cole, Gabriel O. ¹, Sather, Blythe D. ⁴, Song, Xiaoling ³, Thomas, Sushma ¹, Wood, Brent L. ⁵, Blake, Michelle ⁴, Works, Melissa G. ⁴, Shadman, Mazyar ^{1, 2, 3}, Liang, Emily C. ^{1, 2}, Wu, Vicky Q. ¹, Voutsinas, Jenna M. ¹, Gooley, Ted A. ¹, Turtle, Cameron J. ^{1, 2, 3}, Till, Brian G. ^{1, 2, 3}, Coffey, David G. ^{1, 2, 6}, Maloney, David G. ^{1, 2, 3}, Riddell, Stanley R. ^{1, 3}, Green, Damian J. ^{1, 2, 3, 6, 7, ∗}

Source: In Blood March 2025

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis

Authors: Shadman, Mazyar ^{1, ∗}, Brown, Jennifer R. ², Mohseninejad, Leyla ³, Yang, Keri ⁴, Burnett, Heather ⁵, Neupane, Binod ⁵, Williams, Rhys ⁴, Lamanna, Nicole ⁶, O'Brien, Susan M. ⁷, Tedeschi, Alessandra ⁸, Tam, Constantine S. ⁹

Source: In Blood Advances March 2025

Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma

Authors: Khan, Niloufer ^{1, 2, ∗}, Dahi, Parastoo B. ^{3, 4}, Khimani, Farhad ⁵, Shustov, Andrei R. ⁶, Shadman, Mazyar ⁶, Ruan, Jia ⁷, Moskowitz, Alison J. ^{1, 2}, Zelenetz, Andrew D. ^{1, 2}, Noy, Ariela ^{1, 2}, Straus, David J. ^{1, 2}, Drullinsky, Pamela ^{1, 2}, Hamilton, Audrey ^{1, 2}, Kumar, Anita ^{1, 2}, Sauter, Craig S. ^{2, 3}, Shah, Gunjan L. ^{2, 3}, Matasar, Matthew J. ^{1, 2}, Drill, Esther ⁸, Davey, Theresa ¹, Hancock, Helen ¹, Ganesan, Nivetha ¹, Galasso, Natasha ¹, van Beisen, Koen ⁷, Giralt, Sergio ^{2, 3}, Horwitz, Steven M. ^{1, 2}

Source: In Blood Advances December 2024

Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma

Authors: Samples, Laura ^{1, 2, ∗∗}, Sadrzadeh, Hossein ³, Frigault, Matthew J. ⁴, Jacobson, Caron A. ⁵, Hamadani, Mehdi ⁶, Gurumurthi, Ashwath ⁷, Strati, Paolo ⁷, Shouval, Roni ⁸, Noy, Ariela ⁸, Riedell, Peter A. ⁹, Dahiya, Saurabh ¹⁰, Maloney, David G. ^{1, 2}, Till, Brian G. ^{1, 2}, Hirayama, Alexandre V. ^{1, 2}, Gauthier, Jordan ^{1, 2}, Gopal, Ajay K. ^{1, 2}, Smith, Stephen D. ^{1, 2}, Poh, Christina ^{1, 2}, Lynch, Ryan ^{1, 2}, Ujjani, Chaitra ^{1, 2}, Di, Mengyang ^{1, 2}, Raghunathan, Vikram ^{1, 2}, Shakib-Azar, Mehrdad ¹, Naresh, Kikkeri N. ^{1, 2}, Gooley, Ted A. ¹, Yared, Jean ¹¹, Jain, Michael D. ¹², Locke, Frederick L. ¹², Leslie, Lori Ann ¹³, Epperla, Narendranath ¹⁴, Ghosh, Monalisa ¹⁵, Skarbnik, Alan ¹⁶, Hill, Brian T. ¹⁷, Kamdar, Manali K. ¹⁸, Ortiz-Maldonado, Valentin ¹⁹, Martinez-Cibrian, Nuria ¹⁹, Shune, Leyla ²⁰, Shadman, Mazyar ^{1, 2, ∗}

Source: In Blood January 2025

Perspectives on Current Challenges and Emerging Approaches for Lymphoma Management From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference

Authors: Danilov, Alexey V. ^{1, ⁎}, Sauter, Craig ², Phillips, Tycel ¹, Coombs, Catherine C. ³, Ip, Andrew ⁴, Wang, Yucai ⁵, Rhodes, Joanna ⁶, Leslie, Lori ⁷, Barrientos, Jacqueline ⁸, Saeed, Hayder ⁹, Strati, Paolo ¹⁰, Barta, Stefan K. ¹¹, Shadman, Mazyar ¹²

Source: In Clinical Lymphoma, Myeloma and Leukemia January 2025

Chimeric Antigen Receptor-T Cells in the Modern Era of Chronic Lymphocytic Leukemia Treatment.

Authors: Hatashima, Alycia¹ (AUTHOR), Shadman, Mazyar^2,3 (AUTHOR), Raghunathan, Vikram^2,3 (AUTHOR) vraghun@uw.edu

Source: Cancers. Jan2025, Vol. 17 Issue 2, p268. 28p.

Subject Terms: *THERAPEUTIC use of antineoplastic agents, *CHRONIC lymphocytic leukemia diagnosis, *CHRONIC lymphocytic leukemia, *CANCER relapse, *T cells, *ANTINEOPLASTIC agents, *IMMUNOTHERAPY, *PROTEIN-tyrosine kinase inhibitors, *CELLULAR therapy, *DRUG approval, *CANCER chemotherapy, *CELL receptors, *DISEASE progression, *PHARMACODYNAMICS

Company/Entity: UNITED States. Food & Drug Administration

Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors: Shadman, Mazyar¹ (AUTHOR) mshadman@fredhutch.org, Salkar, Monika² (AUTHOR), Srivastava, Bhavini² (AUTHOR), Karve, Sudeep² (AUTHOR), Emond, Bruno³ (AUTHOR), Gogna, Priyanka³ (AUTHOR), Manceur, Ameur M.³ (AUTHOR), Lafeuille, Marie-Hélène³ (AUTHOR), Rava, Andrew⁴ (AUTHOR), Sun, Haiyan⁴ (AUTHOR), Howarth, Amanda⁴ (AUTHOR), Tomicki, Samantha⁴ (AUTHOR), Agatep, Barnabie⁵ (AUTHOR), Jones, Barton⁵ (AUTHOR), Franceschini, Erin² (AUTHOR), Saifan, Chadi² (AUTHOR), Bacchus, Shaffee² (AUTHOR), Roeker, Lindsey⁶ (AUTHOR), Stephens, Deborah M.⁷ (AUTHOR)

Source: Leukemia & Lymphoma. Jan2025, Vol. 66 Issue 1, p44-53. 10p.

Subject Terms: *CHRONIC lymphocytic leukemia, *MEDICAL care costs, *FEE for service (Medical fees), *CARDIAC patients, *DATABASES

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE

Authors: Brown, Jennifer R. ^{1, ∗}, Eichhorst, Barbara ², Lamanna, Nicole ³, O’Brien, Susan M. ⁴, Tam, Constantine S. ^{5, 6}, Qiu, Lugui ⁷, Jurczak, Wojciech ⁸, Zhou, Keshu ⁹, Šimkovič, Martin ^{10, 11}, Mayer, Jiří ¹², Gillespie-Twardy, Amanda ¹³, Ferrajoli, Alessandra ¹⁴, Ganly, Peter S. ¹⁵, Weinkove, Robert ^{16, 17}, Grosicki, Sebastian ¹⁸, Mital, Andrzej ¹⁹, Robak, Tadeusz ²⁰, Osterborg, Anders ^{21, 22}, Yimer, Habte A. ²³, Wang, Megan ²⁴, Salmi, Tommi ²⁵, Wang, Liping ²⁶, Li, Jessica ²⁶, Wu, Kenneth ²⁴, Cohen, Aileen ²⁴, Shadman, Mazyar ^{27, 28}

Source: In Blood 26 December 2024 144(26):2706-2717

CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma

Authors: Pophali, Priyanka A., Fein, Joshua A., Ahn, Kwang W., Allbee-Johnson, Molly, Ahmed, Nausheen, Awan, Farrukh T., Farhan, Shatha, Grover, Natalie S., Hilal, Talal, Iqbal, Madiha, Maakaron, Joseph, Modi, Dipenkumar, Nasrollahi, Elham, Schachter, Levanto G., Sauter, Craig, Hamadani, Mehdi, Herrera, Alex, Shouval, Roni, Shadman, Mazyar

Source: In Blood Advances 22 October 2024 8(20):5290-5296

Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation

Authors: Iqbal, Madiha, Kumar, Ambuj, Dreger, Peter, Chavez, Julio, Sauter, Craig S., Sureda, Anna M., Bachanova, Veronika, Maziarz, Richard T., Dreyling, Martin, Smith, Sonali M., Jacobson, Caron, Glass, Bertram, Casulo, Carla, Oluwole, Olalekan O., Montoto, Silvia, Advani, Ranjana, Cohen, Jonathon, Salles, Gilles, Hamad, Nada, Kuruvilla, John, Kahl, Brad S., Shadman, Mazyar, Kanate, Abraham S., Budde, Lihua Elizabeth, Kamdar, Manali, Flowers, Christopher, Hamadani, Mehdi, Kharfan-Dabaja, Mohamed A.

Source: In Transplantation and Cellular Therapy September 2024 30(9):832-843

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Authors: Locke, Frederick L., Siddiqi, Tanya, Jacobson, Caron A., Ghobadi, Armin, Ahmed, Sairah, Miklos, David B., Perales, Miguel-Angel, Munoz, Javier, Fingrut, Warren B., Pennisi, Martina, Gauthier, Jordan, Shadman, Mazyar, Gowda, Lohith, Mirza, Abu-Sayeef, Abid, Muhammad Bilal, Hong, Sanghee, Majhail, Navneet S., Kharfan-Dabaja, Mohamed A., Khurana, Arushi, Badar, Talha, Lin, Yi, Bennani, N. Nora, Herr, Megan M., Hu, Zhen-Huan, Wang, Hai-Lin, Baer, Anjani, Baro, Elande, Miao, Harry, Spooner, Clare, Xu, Hairong, Pasquini, Marcelo C.

Source: In Blood 27 June 2024 143(26):2722-2734

Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study

Authors: Samples, Laura, Voutsinas, Jenna, Fakhri, Bita, Khajavian, Sirin, Spurgeon, Stephen, Stephens, Deborah, Skarbnik, Alan, Mato, Anthony, Broome, Catherine, Gopal, Ajay, Smith, Stephen, Lynch, Ryan, Rainey, Magdalena, Kim, Myung Sun, Barrett-Campbell, Odeth, Hemond, Emily, Tsang, Mazie, Ermann, Daniel, Malakhov, Nikita, Rao, Danielle, Shakib-Azar, Mehrdad, Morrigan, Beth, Chauhan, Ayushi, Plate, Thomas, Gooley, Ted, Ryan, Kellie, Lansigan, Frederick, Hill, Brian, Pongas, Georgios, Parikh, Sameer A., Roeker, Lindsey, Allan, John N., Cheng, Richard, Ujjani, Chaitra, Shadman, Mazyar

Source: In Blood Advances 14 May 2024 8(9):2085-2093

Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial

Authors: Matasar, Matthew, Bartlett, Nancy L., Shadman, Mazyar, Budde, Lihua E., Flinn, Ian, Gregory, Gareth P., Kim, Won Seog, Hess, Georg, El-Sharkawi, Dima, Diefenbach, Catherine S., Huang, Huang, To, Iris, Parreira, Joana, Wu, Mei, Kwan, Antonia, Assouline, Sarit

Source: In Clinical Lymphoma, Myeloma and Leukemia April 2024 24(4):240-253

Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma

Authors: Hirayama, Alexandre V., Kimble, Erik L., Wright, Jocelyn H., Fiorenza, Salvatore, Gauthier, Jordan, Voutsinas, Jenna M., Wu, Qian, Yeung, Cecilia C. S., Gazeau, Nicolas, Pender, Barbara S., Kirchmeier, Delaney R., Torkelson, Aiko, Chutnik, Abigail N., Cassaday, Ryan D., Chapuis, Aude G., Green, Damian J., Kiem, Hans-Peter, Milano, Filippo, Shadman, Mazyar, Till, Brian G., Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.

Source: In Blood Advances 23 January 2024 8(2):453-467